Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?

Best Practice and Research: Clinical Haematology

Volumn 20, Issue 1, 2007, Pages 29-37

  Larson, Richard A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

AML; cytogenetic abnormalities; outcomes; secondary leukemia

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CARCINOGEN; CYTARABINE; DAUNORUBICIN; GYRASE INHIBITOR; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHRONIC DISEASE; CORRELATION ANALYSIS; DYSPLASIA; FREQUENCY ANALYSIS; GENETIC RISK; GENETIC VARIABILITY; HUMAN; KARYOTYPING; MOLECULAR GENETICS; MONOSOMY 7; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; OUTCOMES RESEARCH; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SECOND CANCER; SURVIVAL TIME; TRISOMY 8;

ACUTE DISEASE; CHROMOSOME ABERRATIONS; HUMANS; LEUKEMIA, MYELOID; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 33847178295     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2006.10.006     Document Type: Review

References (23)

1. Preisler H.D. Evolution of secondary hematologic disorders: preMDS-->MDS-->sAML. Cancer Treatment and Research 108 (2001) 185-230
2. Leone G., Mele L., Pulsoni A., et al. The incidence of secondary leukemias. Haematologica 84 (1999) 937-945
3. Harris N.L., Jaffe E.S., Diebold J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. Journal of Clinical Oncology 17 (1999) 3835-3849
4. Brunning R.D., Matutes E., Harris N.L., et al. Acute myeloid leukemia. In: Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. (Eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues (2001), IARC Press, Lyon, France 88-89
5. Thirman M.J., and Larson R.A. Therapy-related myeloid leukemia. In: Nimer S.D., and Golde D.W. (Eds). Hematologic Complications of Cancer. Hematology/Oncology Clinics of North America 10 (1996) 293-320
6. Godley L.A., and Larson R.A. The syndrome of therapy-related myelodysplasia and myeloid leukemia. In: Bennett J.M. (Ed). The Myelodysplastic Syndromes. Pathobiology and Clinical Management (2002), Marcel Dekker, New York 139-176
7. Offman J., Opelz G., Doehler B., et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood 104 (2004) 822-828
8. Lan Q., Zhang L., Li G., et al. Hematotoxicity in workers exposed to low levels of benzene. Science 306 (2004) 1774-1776
9. Rinsky R.A., Smith A.B., Hornung R., et al. Benzene and leukemia. An epidemiologic risk assessment. The New England Journal of Medicine 316 (1987) 1044-1050
10. Henshaw D.L., Eatough J.P., and Richardson R.B. Radon as a causative factor in induction of myeloid leukaemia and other cancers. Lancet 335 (1990) 1008-1012
11. Crane M.M., Strom S.S., Halabi S., et al. Correlation between selected environmental exposures and karyotype in acute myelocytic leukemia. Cancer Epidemiology, Biomarkers and Prevention 5 (1996) 639-644
12. Gajewski J.L., Ho W.G., Nimer S.D., et al. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. Journal of Clinical Oncology 7 (1989) 1637-1645
13. Haferlach T., Schoch C., Loffler H., et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. Journal of Clinical Oncology 21 (2003) 256-265
14. Goasguen J.E., Matsuo T., Cox C., et al. Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival. Leukemia 6 (1992) 520-525
15. Bennett J.M. Morphologic dysplasia in acute myeloid leukemia: importance of granulocytic dysplasia. Journal of Clinical Oncology 21 (2003) 3004
16. Haferlach T., Kern W., Schoch C., et al. Morphologic dysplasia in acute myeloid leukemia: importance of garnulcytic dysplasia. Journal of Clinical Oncology 21 (2003) 3004-3005
17. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML10 trial. Blood 92 (1998) 2322-2333
18. Grimwade D., Walker H., Harrison G., et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98 (2001) 1312-1320
19. Smith S.M., Le Beau M.M., Huo D., et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 102 (2003) 43-52
20. Schoch C., Kern W., Schnittger S., et al. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 18 (2004) 120-125
21. Kern W., Haferlach T., Schnittger S., et al. Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. Journal of Clinical Oncology 22 (2004) 2510-2511
22. Andersen M.K., and Pedersen-Bjergaard J. Therapy-related MDS and AML in acute promyelocytic leukemia. Blood 100 (2002) 1928-1929
23. Andersen M.K., Larson R.A., Mauritzson N., et al. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 33 (2002) 395-400